---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-000155"
form_type: "8-K"
ticker: "BCRX"
cik: "0000882796"
company_name: "BIOCRYST PHARMACEUTICALS INC"
filed_at: "2025-01-10T23:59:59+00:00"
generated_at: "2026-05-28T06:01:29.814937+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# BioCryst reports FY2024 ORLADEYO net revenue $437M (+34% YoY), guides FY2025 $515-535M

## Summary
- Preliminary FY2024 ORLADEYO net revenue $437M (+34% YoY); Q4 net revenue $123.5M (+36% YoY).
- Total FY2024 revenue $450M (+36% YoY); FY2025 total revenue guidance $540-560M.
- Expects to approach quarterly EPS profitability and positive cash flow in 2H 2025; targets full-year EPS profitability and positive cash flow in 2026.
- Plans 2025 NDA for ORLADEYO granules for children <12; two new pipeline programs to enter clinic (BCX17725, avoralstat).
- 2025 GAAP op ex guidance $485-495M (incl. ~$60M stock comp); non-GAAP op ex $425-435M.

## SEC filing metadata
- accession: 0001171843-25-000155
- form_type: 8-K
- ticker: BCRX
- cik: 0000882796
- company_name: BIOCRYST PHARMACEUTICALS INC
- filed_at: 2025-01-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882796/000117184325000155/0001171843-25-000155-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882796/000117184325000155/f8k_011025.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-000155
- JSON: https://secwatch.observer/filing/0001171843-25-000155.json
- Plain text: https://secwatch.observer/filing/0001171843-25-000155.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.